Saigenci Embl Australia Group Leader

**(Level C) $125, 537 to $144,368 per annum or (Level D) $150,639 to $165,698 per annum plus an employer contribution of up to 17% superannuation may apply**

**Fixed term, full-time position available for five years**

**Exciting opportunity to join EMBLAustralia and SAiGENCI as Group Leader in Cancer Research**

**Further information regarding this opportunity can be found here**:
SAiGENCI operates as an independent institute within the University of Adelaide and in alliance with the Central Adelaide Local Health Network (CALHN). SAiGENCI supports and promotes collaborations with other cancer research centres in Australia. SAiGENCI aims to develop the highest quality scientific program to achieve its chief goal of making discoveries to decrease the burden of cancer, by attracting and retaining brilliant biomedical and clinical researchers. The Institute will also have a global reach by collaborating with likeminded centres of excellence across the globe.

SAiGENCI will provide a focal point for cancer research in the South Australian Biomedical Precinct and through this, enable South Australian participation in the developing Australian network of cancer institutes, and national and international clinical trials partnerships. In so doing, SAiGENCI will help develop world-class and life-changing treatments and improve the outcomes of patients with cancer.

**SAiGENCI will**
- Have four core scientific programs; Resistance Prevention, Cancer Epigenetics, Computational Systems Oncology, and Tumour Inflammation and Immunotherapy.
- Have a core of high performing groups across its programs, with a distinct institutional culture. Each Group Leader will be leaders at a state, national and international level as unique investigators while also supporting collaborations with other cancer research groups across South Australia and Australia.
- SAiGENCI and the University of Adelaide will provide Group Leaders early in their career with a supportive environment to achieve highly ambitious research goals.
- Utilise the close links to the Australian Bragg Proton Therapy Beam, which is Australia’s first proton therapy centre and the first of its kind in the Southern Hemisphere.

We are now seeking to recruit an outstanding Research Group Leader who will head up an independent research team undertaking research within one of four program themes:
**Resistance Prevention**

The program will work on understanding the mechanisms underlying response and resistance to contemporary cancer therapies. It is envisaged that laboratory findings will be translated directly from bench to bedside through clinical trials.

**Cancer Epigenetics**

The Cancer Epigenetic program, led by Professor Jose Polo, combines Cancer, Reprogramming and Epigenetics, using expertise in cellular reprogramming, epigenetics, stem cell biology and the characterisation of rare cell populations. In the last 14 years there has been a revolution in this field, leading to an explosion in the use of reprogramming in potential cellular therapies. This process can inform and help in cancer biology research. Tools and analytical methods to facilitate the understanding of the epigenetic mechanism underpinning several tumorigenic processes will be developed, where epigenetic and reprogramming research will also allow the discovery of new targets and, ultimately, therapies.

**Computational Systems Oncology**

The expert Computational Systems Biologist and Bioinformatics program, led by Professor Melissa Davis will create a centre of research excellence in advanced computational systems biology, taking advantage of novel technologies and high-density data from the clinic and laboratory, to develop new methods and research programs that will form an integral part of all of the basic and translational research excellence at SAiGENCI. The team is proving to act as a catalyst for several important relationships in computing and data analysis, enhancing the existing strengths of the University through the Australian Institute for Machine Learning (AIML) and other partners at SAHMRI.

**Tumour Inflammation and Immunotherapy**

The successful applicant will also participate in the collegial, collaborative culture of SAiGENCI as well as the EMBL Australia Partner Laboratory Network (PLN). They will actively support the development of the PLN by participating in the various programs aimed at increasing research excellence and internationalisation.

EMBL Australia and The University of Adelaide are committed to supporting a gender-diverse and inclusive work environment, ensuring equal employment opportunity to attract and retain the best in their field. Attractive conditions and benefits are offered to ensure a flexible and family-friendly working environment.

**About EMBL Australia**

Australia is the first Associate Member of the European Molecular Biology Laboratory (EMBL). EMBL is an international research organisation that fosters excellence by providing a highly colla